Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 12/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287558 | 0.84 | P4HTM (0.53) | KMT2AALOX15GFERADAM17P4HTM | |
| SCHEMBL2588671 | 0.83 | KMT2A (0.49) | LMNAKMT2AALOX15GFERADAM17 | |
| SCHEMBL18496815 | 0.80 | P4HTM (0.42) | BACE1P4HTM | |
| SCHEMBL30640076 | 0.80 | MAPK1 (0.56) | LMNAKMT2AALOX15GFERADAM17 | |
| SCHEMBL2108310 | 0.80 | MAPK1 (0.56) | LMNAKMT2AALOX15GFERADAM17 | |
| SCHEMBL7709287 | 0.79 | ABL1 (0.39) | LMNAKMT2AALOX15GFERADAM17 | |
| Formic Acid SCHEMBL2584800 | 0.78 | KMT2A (0.44) | LMNAKMT2AALOX15GFERADAM17 | |
| SCHEMBL21096166 | 0.77 | KMT2A (0.56) | LMNAKMT2AGRM4BACE1BACE2 | |
| SCHEMBL11192069 | 0.77 | DRD3 (0.46) | KMT2AP4HTM | |
| SCHEMBL2891190 | 0.76 | GABRA1 (0.46) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696691-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190270757-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-05 | — | — | US | disclosed |
| EP-3334742-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| CN-106795177-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2019-04-23 | — | — | CN | disclosed |
| US-10246468-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190002476-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2019-01-03 | — | — | US | disclosed |
| EP-3204391-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-3334742-A1 | BACE1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-06-20 | — | — | EP | disclosed |
| CN-107683283-A | Bace1 inhibitor | 豪夫迈·罗氏有限公司 | 2018-02-09 | — | — | CN | disclosed |
| EP-3204391-A1 | BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| CN-106795177-A | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2017-05-31 | — | — | CN | disclosed |
| WO-2017025491-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| US-9540397-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2016055496-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102105-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696691-B2 | BACE1 inhibitors | BACE1, BACE2, APP | LMNA 1143/4885KMT2A 2749/4885ALOX15 1428/4885 |
| US-10246468-B2 | BACE1 inhibitors | BACE1, BACE2, APP | LMNA 1187/4885KMT2A 2748/4885ALOX15 1323/4885 |
| US-20160102105-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | LMNA 1143/4885KMT2A 2749/4885ALOX15 1428/4885 |
| US-20190270757-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | LMNA 1143/4885KMT2A 2749/4885ALOX15 1428/4885 |
| US-20190002476-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | LMNA 1143/4885KMT2A 2749/4885ALOX15 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.